Subarachnoid Hemorrhage — Evaluation of the Level and Prognostic Relevance of New Neuroinflammation Markers in Subarachnoid Haemorrhage
Citation(s)
Huang M, Hu YY, Dong XQ High concentrations of procoagulant microparticles in the cerebrospinal fluid and peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome. Surg Neurol. 2009 Nov;72(5):481-9; discussion 489. doi: 10.1016/j.surneu.2008.12.016. Epub 2009 Mar 27.
Schroeter M, Zickler P, Denhardt DT, Hartung HP, Jander S Increased thalamic neurodegeneration following ischaemic cortical stroke in osteopontin-deficient mice. Brain. 2006 Jun;129(Pt 6):1426-37. doi: 10.1093/brain/awl094. Epub 2006 Apr 24.
Zhou C, Yamaguchi M, Colohan AR, Zhang JH Role of p53 and apoptosis in cerebral vasospasm after experimental subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2005 May;25(5):572-82. doi: 10.1038/sj.jcbfm.9600069.
Evaluation of New Neuroinflammation Markers in Subarachnoid Haemorrhage Patients: a Pilot Study
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
